• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of brjopthalBritish Journal of OphthalmologyCurrent TOCInstructions for authors
Br J Ophthalmol. Oct 1997; 81(10): 867–870.
PMCID: PMC1722025

A double masked comparison of the intraocular pressure reducing effect of latanoprost 0.005% and 0.001% administered once daily in open angle glaucoma and ocular hypertension

Abstract

AIM—To compare the intraocular pressure (IOP) reducing effect of latanoprost 0.005% and 0.001%.
METHODS—Twenty four patients with glaucoma or ocular hypertension were randomised into two groups. Twelve patients (group 1) were given latanoprost 0.005% once daily for 4 weeks and then latanoprost 0.001% once daily for the following 4 weeks. Twelve patients (group 2) were given latanoprost 0.001% once daily for 4 weeks and then latanoprost 0.005% for the following 4 weeks.
RESULTS—There was a significant IOP reduction from baseline in both groups on day 28 as well as on day 56. When the results from both groups were used for calculations, the mean IOP reduction from baseline after 4 weeks of treatment with latanoprost 0.005% (day 28 or 56) was 9.6 (SD 3.3) mm Hg (35.0%). After 4 weeks of treatment with latanoprost 0.001%, the IOP reduction (day 28 or 56) was 7.6 (3.4) mm Hg (27.7%). The difference in IOP reduction between the two concentrations was 2.0 (2.3) mm Hg (p<0.001).
CONCLUSIONS—Latanoprost 0.005% was more effective than latanoprost 0.001% in reducing IOP. Even the lower concentration was surprisingly effective, and potentially may be of importance for use in clinical practice. Furthermore, it is at present unknown whether the increase in iris pigmentation seen in certain patients treated with latanoprost 0.005% is dose dependent and might be less pronounced with latanoprost 0.001%. Long term studies with a larger number of patients are required in order to answer this question.

Full Text

The Full Text of this article is available as a PDF (124K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Alm A, Villumsen J. PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers. Arch Ophthalmol. 1991 Nov;109(11):1564–1568. [PubMed]
  • Villumsen J, Alm A. PhXA34--a prostaglandin F2 alpha analogue. Effect on intraocular pressure in patients with ocular hypertension. Br J Ophthalmol. 1992 Apr;76(4):214–217. [PMC free article] [PubMed]
  • Camras CB, Schumer RA, Marsk A, Lustgarten JS, Serle JB, Stjernschantz J, Bito LZ, Podos SM. Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension. Arch Ophthalmol. 1992 Dec;110(12):1733–1738. [PubMed]
  • Friström B, Nilsson SE. Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure. Arch Ophthalmol. 1993 May;111(5):662–665. [PubMed]
  • Alm A, Villumsen J, Törnquist P, Mandahl A, Airaksinen J, Tuulonen A, Marsk A, Resul B, Stjernschantz J. Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study. Ophthalmology. 1993 Sep;100(9):1312–1317. [PubMed]
  • Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993 Oct;111(10):1351–1358. [PubMed]
  • Nagasubramanian S, Sheth GP, Hitchings RA, Stjernschantz J. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens. Ophthalmology. 1993 Sep;100(9):1305–1311. [PubMed]
  • Alm A, Widengård I, Kjellgren D, Söderström M, Friström B, Heijl A, Stjerschantz J. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol. 1995 Jan;79(1):12–16. [PMC free article] [PubMed]
  • Gabelt BT, Kaufman PL. Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res. 1989 Sep;49(3):389–402. [PubMed]
  • Nilsson SF, Samuelsson M, Bill A, Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey. Exp Eye Res. 1989 May;48(5):707–716. [PubMed]
  • Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993 Sep;100(9):1297–1304. [PubMed]
  • Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993 Oct;111(10):1351–1358. [PubMed]
  • Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology. 1996 Jan;103(1):138–147. [PubMed]
  • Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology. 1996 Jan;103(1):126–137. [PubMed]
  • Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995 Dec;102(12):1743–1752. [PubMed]

Figures and Tables

Figure 1
Reduction in intraocular pressure (IOP) from baseline (day 1) on days 28 and 56. Group 1, treatment with latanoprost 0.005% once daily at 8 pm from day 1 to day 27 and with latanoprost 0.001% once daily ...
Figure 2
Reduction in intraocular pressure (IOP) from baseline (day 1) by time of day on days 28 and 56. Group 1, treatment with latanoprost 0.005% once daily at 8 pm from day 1 to day 27 and with latanoprost 0.001% ...

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Group

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • Compound
    Compound
    PubChem Compound links
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...